• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over

by December 19, 2024
written by December 19, 2024

Investing.com — Eli Lilly was slightly lower Thursday even as the Federal Drug Administration confirmed that a shortage of the diabetes and weight-loss drug tirzepatide was over.

Eli Lilly and Company (NYSE:LLY) was slightly lower in recent trading.

“FDA has determined that the shortage of tirzepatide injection products, which first began in December 2022, is resolved,” the FDA said Thursday.

The FDA announced in October that a shortage of tirzepatide, the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — was over. The decision, however, was challenged by the Outsourcing Facilities Association, a trade group representing compounding pharmacies making generic or compounded versions of the tirzepatide, who said it was still in short supply. 

During the reassessment phase, compounding pharmacies were permitted to continue producing generic versions of tirzepatide, but now have 60 days to stop making compounded versions of the drug.

The FDA concluded that “that the information and data Lilly has provided to FDA demonstrate that Lilly’s supply is currently meeting or exceeding demand for these drug products.”

Eli Lilly has also “scheduled substantial additional production over the coming months, such that supply will meet or exceed projected demand,” it added.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Kinder Morgan subsidiary moves forward with $1.4b Mississippi Crossing Project
next post
Prothena stock soars despite study miss

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Robust US jobs report increases odds of no-landing: BCA
    • The five charts flashing red for U.S. equity bulls: McGeever

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy